Eiger BioPharmaceuticals

$10.17
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.27 (-2.59%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell EIGR and other stocks, options, and ETFs commission-free!

About EIGR

Eiger BioPharmaceuticals, Inc. Common Stock, also called Eiger BioPharmaceuticals, is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA. The listed name for EIGR is Eiger BioPharmaceuticals, Inc. Common Stock.

CEO
David A. Cory
Employees
24
Headquarters
Palo Alto, California
Founded
2008
Market Cap
335.60M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
194.70K
High Today
$10.69
Low Today
$9.99
Open Price
$10.50
Volume
167.70K
52 Week High
$13.99
52 Week Low
$4.55

EIGR Earnings

-$0.76
-$0.51
-$0.25
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 12, After Hours

You May Also Like

CSTA=
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure